UNSPSC 51381903: Mofezolac

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H17NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RVJ0BV3H3Y, chemically known as 3,4-bis(p-methoxyphenyl)-5-isoxazoleacetic acid but generally known as mofezolac, which bears US NIH Compound Identifier 4237. European Medicines Agency schedules Mofezolac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09035MIG.

UNSPSC 51381903 Mofezolac is a Commodity code that represents pharmaceutical products procured by state and local health agencies, though the recent opportunities tagged under this code show minimal direct alignment with mofezolac specifically. State and local governments buying under this code are acquiring generic multi-source pharmaceuticals, naloxone (opioid antagonist), and over-the-counter products through cooperative purchasing agreements and direct competitive procurements. The issuing bodies include state health commissions, county health departments, and multistate cooperative purchasing alliances that aggregate demand across multiple jurisdictions and facility networks.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida posted IFB60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries due July 26, 2026 (note: the source contains a date inconsistency, listing both 2023 and 2026). The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program. Most significantly, the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with responses due March 26, 2026, covering multiple participating states including Oregon. The MMCAP procurement requires manufacturers to supply through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), comply with cGMP and DSCSA, maintain $5 million commercial general liability coverage, and accept a 3 percent administrative fee with performance penalties of $200 to $1,500 per violation. Contract terms are two years for new vendors with optional extensions.